Conferences - Results from #7760

FOIU 2018: Intermittent vs. Continuous ADT July 6, 2018

FOIU 2018: Is there a "Cardio-friendly" ADT? July 6, 2018

FOIU 2018: Epidemiology: The RADICAL PC Trial July 6, 2018

FOIU 2018: FSH as a Modulator of Cardiovascular Events in ADT Recipients July 6, 2018

FOIU 2018: How ADT Accelerates Cardiovascular Disease July 6, 2018

FOIU 2018: Testosterone and Cardiovascular Mortality July 6, 2018

FOIU 2018: Novel Targeted Androgen Ablation Prior to Radical Prostatectomy July 6, 2018

FOIU 2018: The Role of Radical Prostatectomy in Locally Advanced and Oligometastatic High Risk Prostate Cancer July 5, 2018

FOIU 2018: Optimizing the Management of High Risk Prostate Cancer with Radiotherapy July 5, 2018

FOIU 2018: Should the Primary Be Treated in Patients with Metastatic Disease? - Testicular Cancer July 5, 2018

FOIU 2018: Aggressive and Unusual Subtypes of Prostate Cancer July 5, 2018

FOIU 2018: Should the Primary Be Treated in Patients with Metastatic Disease? - Upper Tract Urothelial Cancer July 5, 2018

FOIU 2018: Should the Primary Be Treated in Patients with Metastatic Disease? - Kidney Cancer July 5, 2018

FOIU 2018: Bladder Cancer – Oncologist’s View July 5, 2018

FOIU 2018: Oncologist View - Local Treatment of Metastatic Prostate Cancer July 4, 2018

FOIU 2018: Should the Primary Be Treated in Patients with Metastatic Disease? - Prostate Cancer July 4, 2018

FOIU 2018: Does Checkpoint Inhibition Work in Prostate Cancer? July 4, 2018

FOIU 2018: Current Experience in Immunotherapy for Metastatic Renal Cell Carcinoma July 4, 2018

FOIU 2018: Immune-Oncology In Genitourinary Malignancies - Have We All Been Too Enthusiastic Too Soon? July 4, 2018

FOIU 2018: Current Experience in Immunotherapy for Metastatic Bladder Cancer July 4, 2018

Page 389 of 616